These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 26202207)

  • 21. Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials.
    De Luca G; Verdoia M; Suryapranata H
    Atherosclerosis; 2012 Jun; 222(2):426-33. PubMed ID: 22483166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcomes comparing eptifibatide and abciximab in ST elevation acute myocardial infarction patients undergoing percutaneous coronary interventions.
    Midei MG; Coombs VJ; Lowry DR; Drossner MN; Prewitt KC; Wang JC; Loughrey MB; Gottlieb SO
    Cardiology; 2007; 107(3):172-7. PubMed ID: 16940721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic effect of thrombus aspiration and abciximab in primary percutaneous coronary intervention.
    Pyxaras SA; Mangiacapra F; Verhamme K; Di Serafino L; De Vroey F; Toth G; Perkan A; Salvi A; Bartunek J; De Bruyne B; Wijns W; Sinagra G; Barbato E
    Catheter Cardiovasc Interv; 2013 Oct; 82(4):604-11. PubMed ID: 23359568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Guagliumi G; Stone GW; Cox DA; Stuckey T; Tcheng JE; Turco M; Musumeci G; Griffin JJ; Lansky AJ; Mehran R; Grines CL; Garcia E
    Circulation; 2004 Sep; 110(12):1598-604. PubMed ID: 15353506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy.
    Sibbing D; Bernlochner I; Schulz S; Massberg S; Schömig A; Mehilli J; Kastrati A
    J Am Coll Cardiol; 2012 Jul; 60(5):369-77. PubMed ID: 22682553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transradial approach in patients with ST-elevation myocardial infarction treated with abciximab results in fewer bleeding complications: data from EUROTRANSFER registry.
    Siudak Z; Zawislak B; Dziewierz A; Rakowski T; Jakala J; Bartus S; Noworolnik B; Zasada W; Dubiel JS; Dudek D
    Coron Artery Dis; 2010 Aug; 21(5):292-7. PubMed ID: 20453640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Procedural and clinical outcomes after use of the glycoprotein IIb/IIIa inhibitor abciximab for saphenous vein graft interventions.
    Harskamp RE; Hoedemaker N; Newby LK; Woudstra P; Grundeken MJ; Beijk MA; Piek JJ; Tijssen JG; Mehta RH; de Winter RJ
    Cardiovasc Revasc Med; 2016; 17(1):19-23. PubMed ID: 26626961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.
    Pinkau T; Ndrepepa G; Kastrati A; Mann JF; Schulz S; Mehilli J; Schömig A
    Cardiology; 2008; 111(4):247-53. PubMed ID: 18434733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
    Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A;
    N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prophylactic abciximab in elective coronary stenting: results of a randomized trial.
    Tamburino C; Russo G; Nicosia A; Galassi AR; Foti R; Scriffignano V; Kereiakes DJ; Giuffrida G
    J Invasive Cardiol; 2002 Feb; 14(2):72-9. PubMed ID: 11818641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Readministration of abciximab in percutaneous coronary intervention.
    Fry ET
    J Invasive Cardiol; 1999 Apr; 11(4):251-8. PubMed ID: 10745525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial.
    Mehilli J; Ndrepepa G; Kastrati A; Neumann FJ; ten Berg J; Bruskina O; Dotzer F; Seyfarth M; Pache J; Kufner S; Dirschinger J; Berger PB; Schömig A
    Am Heart J; 2007 Jul; 154(1):158.e1-7. PubMed ID: 17584569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial center.
    Barthélémy O; Silvain J; Brieger D; Mercadier A; Lancar R; Bellemain-Appaix A; Beygui F; Collet JP; Costagliola D; Montalescot G
    Catheter Cardiovasc Interv; 2012 Jan; 79(1):104-12. PubMed ID: 22162411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A longitudinal analysis of outcomes associated with abciximab and eptifibatide in a consecutive series of 3074 percutaneous coronary interventions.
    Long KH; Ting HH; McMurtry EK; Lennon RJ; Wood DL; Holmes DR; Raveendran G; Rihal CS
    Value Health; 2008; 11(3):462-9. PubMed ID: 18489669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention.
    Fiedler KA; Ndrepepa G; Schulz S; Floh S; Hoppmann P; Kufner S; Bernlochner I; Byrne RA; Schunkert H; Laugwitz KL; Kastrati A
    EuroIntervention; 2016 Feb; 11(11):e1275-82. PubMed ID: 26865445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of abciximab in coronary angioplasty--an Asian centre's experience.
    Tan HC; Lim YT; Lim TT; Cheng A; Chia BL
    Singapore Med J; 2000 Feb; 41(2):69-73. PubMed ID: 11063206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes and costs of abciximab versus eptifibatide for percutaneous coronary intervention.
    Coons JC; Seybert AL; Saul MI; Kirisci L; Kane-Gill SL
    Ann Pharmacother; 2005 Oct; 39(10):1621-6. PubMed ID: 16105872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention.
    Gunasekara AP; Walters DL; Aroney CN
    Int J Cardiol; 2006 Apr; 109(1):16-20. PubMed ID: 16014315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions.
    Ndrepepa G; Kastrati A; Mehilli J; Neumann FJ; ten Berg J; Bruskina O; Dotzer F; Seyfarth M; Pache J; Dirschinger J; Ulm K; Berger PB; Schömig A
    Circulation; 2006 Nov; 114(19):2040-6. PubMed ID: 17060377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.